News

This follows the FDA’s acceptance in February 2018 of an Investigational New Drug (IND) Application by the Company for the potentially ground-breaking drug. Fast Track Designation is one

Akcea, which is an affiliate of Ionis, is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with serious rare diseases. Inotersen is

Foghorn initially commenced operations in 2016, and developed a Gene Traffic Control product platform to discover and develop drugs based on insights into the chromatin regulatory system that

CrownBio provides the world’s largest collection of Patient-Derived Xenograft (PDX) models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments. Phanes

Proteostasis Therapeutics president and CEO Meenu Chhabra said: "This is the second important regulatory designation PTI-428 has been granted from the FDA this week, highlighting our amplifier’s potential to

The trial was evaluating the safety and efficacy of the investigational therapy in ambulatory and non-ambulatory children and adolescents with the genetic disorder. According to Solid Biosciences, the

Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol

The Placing was completed at a subscription price of €9.00 per share and represented 14.8% of the issued share capital of the Company prior to the transaction. The

The company’s supplemental Biologics License Application (sBLA), which has been accepted by the regulator, is seeking approval for treating patients whose cervical cancer had progressed on or after